FDA Approves Lumasiran for PH1: What BD and Investors Should Know

FDA Approves Lumasiran for PH1: What BD and Investors Should Know

This rewrite clarifies that FDA-approved Givlaari (givosiran) is indicated for adults with acute hepatic porphyria, while OXLUMO (lumasiran) is approved for PH1. The article frames the regulatory and portfolio update, not a new AHP label for lumasiran.

Key Takeaways

• Givlaari (givosiran) is FDA-indicated for adults with acute hepatic porphyria (AHP), not lumasiran. Regulatory clarity on asset labels is critical for BD and investor materials.

• Lumasiran (Oxlumo) is FDA-indicated for primary hyperoxaluria type 1 (PH1) in pediatric and adult patients, a distinct rare disease from AHP that requires separate clinical and commercial strategies.

• In clinical trials, givosiran reduced porphyria attacks by 70% versus placebo, anchoring the current AHP treatment standard and informing competitive positioning.

• Active registries and phase 2 trials in both AHP and PH1 represent near-term catalyst opportunities for BD teams tracking durability, real-world evidence, and potential label extensions.

Regulatory Status: Givlaari for AHP, Lumasiran for PH1

The FDA's regulatory approvals for Alnylam's siRNA portfolio require precise categorization. Givlaari (givosiran) is indicated for the treatment of adults with acute hepatic porphyria (AHP). This is a distinct approval from lumasiran (Oxlumo), which is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.

For BD and regulatory teams, this distinction is foundational. The two assets target different rare metabolic disorders, each with separate patient populations, clinical endpoints, and reimbursement pathways. Conflating the approvals in investor materials, partnership discussions, or competitive analyses introduces material error and undermines credibility in due diligence.

How Givosiran Works in Acute Hepatic Porphyria

Givosiran is an siRNA-based treatment for acute hepatic porphyria that inhibits the ALAS1 enzyme in the liver. The mechanism reduces the production of toxic compounds aminolevulinic acid (ALA) and porphobilinogen (PBG)—the biochemical drivers of acute attacks.

The clinical validation came from the ENVISION phase 3 trial, which established that patients with acute hepatic porphyria taking givosiran experienced 70% fewer porphyria attacks compared with placebo. This efficacy signal remains the benchmark for AHP treatment and a key reference point for competitive positioning and patient selection in real-world practice.

Clinical Evidence Anchoring the AHP Treatment Landscape

The ENVISION trial evaluated givosiran efficacy and safety in patients with acute hepatic porphyrias, including acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. The 70% attack reduction versus placebo established givosiran as the first disease-modifying therapy for this patient population and set the clinical standard against which future AHP assets will be measured.

For BD teams evaluating in-licensing opportunities or competitive threats in rare metabolic disease, the ENVISION data remains the reference efficacy comparator. Analysts and investors use this benchmark to assess pipeline candidates and partnership value.

What Lumasiran (Oxlumo) Is and Isn't

Lumasiran is not an AHP therapy. Oxlumo is a HAO1-directed small interfering RNA indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. PH1 is a genetic disorder of oxalate metabolism, entirely distinct from the heme biosynthesis dysfunction that characterizes AHP.

This separation is essential for regulatory submissions, investor communications, and partnership discussions. Misrepresenting lumasiran as an AHP asset in due diligence materials or board presentations creates compliance and reputational risk.

Implications for BD and Regulatory Teams

The immediate action item for pharma BD and regulatory teams is portfolio audit and label precision. Materials, competitive matrices, and investor decks should clearly segregate givosiran (AHP) from lumasiran (PH1). This clarity prevents cross-indication confusion in partnership discussions, licensing negotiations, and analyst briefings.

Second, teams should map the clinical trial landscape for each indication separately. For AHP, the ELEVATE registry is actively recruiting patients with acute hepatic porphyria, representing a real-world evidence and durability catalyst. For PH1, a phase 2 trial is recruiting lumasiran in hyperoxalaemic patients on haemodialysis, signaling potential label expansion or new patient population validation.

Third, regulatory teams should track the distinction in payer and health authority communications. Reimbursement pathways, health technology assessment submissions, and managed-care negotiations will be indication-specific. Conflating the two assets in these discussions delays coverage decisions and complicates market access.

Medications to Avoid in Acute Intermittent Porphyria

Patients with acute intermittent porphyria should avoid certain anti-infectives (such as sulfonamides, erythromycin, and rifampin), sedatives (such as barbiturates and some benzodiazepines), and anti-epileptics (such as phenytoin and carbamazepine). This drug-avoidance profile is critical for patient education and clinical decision support around givosiran therapy, and it should be reflected in any BD materials discussing AHP patient management.

Catalysts to Watch in AHP and PH1

Three active trials represent near-term monitoring points for BD and investor tracking:

ELEVATE Registry (AHP): The ELEVATE registry is currently recruiting patients with acute hepatic porphyria. This observational study will generate real-world evidence on givosiran durability, long-term safety, and clinical outcomes outside controlled trial settings. Registry readouts may inform label updates, payer coverage decisions, or next-generation asset development.

Lumasiran in Haemodialysis (PH1): A phase 2 trial is recruiting lumasiran in hyperoxalaemic patients on haemodialysis. Success here would extend lumasiran's addressable market to advanced chronic kidney disease patients, a significant population expansion and potential catalyst for revenue guidance updates or partnership announcements.

PH1 Observational Registry (BONAPH1DE): The BONAPH1DE prospective observational study of patients with primary hyperoxaluria type 1 is active but not currently recruiting. Once data emerge, this registry will provide real-world safety and efficacy benchmarks for lumasiran in routine clinical practice.

Drug Snapshot

Regulatory Summary

• Approved indication: 1 INDICATIONS AND USAGE OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . OXLUMO is a HAO1 -directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. ( 1 )

• Alnylam Pharmaceuticals, Inc. develops Lumasiran

• Alnylam Pharmaceuticals, Inc. develops Givosiran

Trial Snapshot

Competitor Matrix

Timeline

• Active_Not_Recruiting trial NCT04982393 (phase n/a)

• Recruiting trial NCT06225544 (PHASE2)

• Recruiting trial NCT04883905 (phase n/a)

Frequently Asked Questions

Related profiles

• lumasiran

• givosiran

• ERYTHROMYCIN

• rifampin

• phenytoin

Related coverage

• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain

• GSK’s Blenrep returns to the US market after FDA approves resubmission

• FDA approves Vyloy for HER2-negative gastric and GEJ cancer